• Sitemap
  • Contact Us

pISSN 2950-9114 eISSN 2950-9122
Article View

Report On Proficiency Testing

Lab Med Qual Assur 2022; 44(1): 10-20

Published online March 31, 2022


Copyright © Korean Association of External Quality Assessment Service.

Annual Report of the Korean External Quality Assessment Service on Transfusion Medicine (2021)

Hee-Jeong Youk1 , Jin Seok Kim1 , John Jeongseok Yang1 , Hyungsuk Kim2 , and Dae-Hyun Ko1

1Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine; 2Department of Laboratory Medicine, Seoul National University Hospital, Seoul, Korea

Correspondence to:Dae-Hyun Ko
Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
Tel +82-2-3010-4504
E-mail daehyuni1118@amc.seoul.kr

Hyungsuk Kim
Department of Laboratory Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
Tel +82-2-2072-3500
E-mail hyungsuk_kim@snuh.org

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


This report summarizes the 2021 survey results of the external quality assessment (EQA) scheme for the transfusion medicine program (TMP) in Korea. Proficiency testing materials were prepared at the Asan Medical Center for biannual distribution to participating laboratories. The accuracy rates and number of participating laboratories for the 14 survey items were as follows: ABO typing, 99.6%–100.0%; RhD typing, 99.8%–100.0%; crossmatching, 94.2%–99.0%; ABO subgroup typing, 100.0% in trial 1 and unagreed results in trial 2; Rh CcEe antigen test, 98.3%–100.0%; weak D test, 81.9%–91.6%; Duffy antigen test, 95.8%–100.0%, Lewis antigen test, 95.5%–100.0%; Kidd antigen test, both 100.0%; antibody screening, 99.4%–100.0%; direct antiglobulin test (DAT) using a polyspecific reagent, 99.3%–100.0%; DAT using anti-immunoglobulin-G monospecific reagent, both 100.0%; DAT using anti-C3d monospecific reagent, both 100.0%; antibody identification, 86.9%–100.0%; and ABO antibody titration, 87.5%–100.0%. Although the overall results were excellent, only 67.2% of the participating laboratories precisely determined samples within the ABO subgroup in the EQA conducted in the last half of 2021. The 2021 EQA scheme for TMP has contributed to the program’s improvement and maintenance of the participating laboratories.

Keywords: Transfusion medicine, Quality improvement, Laboratory proficiency testing

Supplementary File

Share this article on :

Stats or metrics